CVS partners with ProKidney to enroll patients for phase 3 cell therapy trial

Preview

来源: FierceBiotech

To help fund the study, ProKidney hauled in $825 million as part of a merger last January with Social Capital Suvretta Holdings Corp. III.

CVS Health Clinical Trial Services, a unit of the pharmacy giant CVS, has signed up to begin enrolling patients for ProKidney’s phase 3 trial of its ReACT cell therapy designed to treat chronic kidney disease.

Under the agreement, CVS Health will recruit participants at 39 sites by using a machine learning model to identify patient populations that align with trial inclusion/exclusion criteria, the company said in a Jan. 31 media advisory. Financial details weren’t disclosed.

ProKidney picked up ReACT when it acquired inRegen for $62 million in 2019. In 2021, the company presented data on 51 type 2 diabetic chronic kidney disease patients who received image-guided injections of autologous renal progenitors across two midphase trials. The treatment is designed to slow, stabilize and reverse decline in kidney function.

If proven effective, ProKidney has forecast the eligible patient population at about 4.4 million. If the company can penetrate just 1% of the addressable market, it has said it could reap as much as $16 billion with the treatment going for $360,000 a patient.

To help fund the study, the company hauled in $825 million as part of a merger last January with Social Capital Suvretta Holdings Corp. III, a SPAC set up by billionaire investor Chamath Palihapitiya and Suvretta Capital.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。